ClinicalTrials.gg
RecruitingNCT06969755BEESTUpdated Jul 31, 2026

Biomarkers to Enhance Early Schizophrenia Treatment

A Phase 4 interventional study of aripiprazole and risperidone in Schizophenia Disorder, sponsored by Northwell Health. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Northwell Health · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Sep 2024, registered Apr 2025).
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Planned enrollment
54th of 125
180 · median 130
Started
2024
with 1 other
Phase 4
56 of 126
2 open now
Registered
124th of 126
by date

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 54th largest by planned enrollment of the 125 interventional ones that give a count, is one of 2 that started in 2024, is one of 56 in phase 4, and was the 124th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.

Read the detailed description

The study is designed to test the hypothesis that, compared with standard treatment with FL-APs (risperidone or aripiprazole), early treatment with clozapine (CLZ) will benefit patients in the first episode of psychosis (FEP) who have been designated three biomarker positive (3B+) as follows: 1) likely to have a poor response to FL-APs; 2) not at heightened risk for clozapine-induced agranulocytosis and 3) not at heightened risk for antipsychotic-induced weight gain. The study will recruit n=410 FEP across the 5 participating sites for screening on each of the 3 biomarkers (striatal connectivity in relation to risk of treatment response/resistance to conventional antipsychotics, MC4R genotype in relation to weight gain risk, and HLA-DQB1 genotype in relation to agranulocytosis risk), which involves a rs-fMRI scan (for response/non-response prediction) and a blood draw for genotyping per above (to screen for heightened risk for each of the two side effects). Those failing to meet any of the 3 biomarker criteria will receive FEP care but will not be enrolled in the study.

03

Conditions studied

  • Schizophenia Disorder

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 35.
  2. DSM5 diagnosis (as determined by the SCID5) of schizophrenia, schizoaffective disorder, schizophreniform disorder.
  3. Current positive symptoms rated ≥4 (moderate) on one or more of the following BPRS positive subscale items: unusual thought content, conceptual disorganization, hallucinatory behavior, suspiciousness.
  4. Preserved striatal connectivity, as determined by screening MRI scan
  5. Absence of the MC4R high-risk genotype, as determined by genetic testing
  6. Absence of the HLA-DQB1 high-risk genotype, as determined by genetic testing
  7. In an early phase of illness as defined by having taken antipsychotic drugs for a cumulative lifetime period of 4 weeks or less (with exceptions of very low doses for other off-label indications, e.g. sleep)
  8. Ability to provide

Exclusion criteria

Exclusion Criteria:

  1. The patient reports or medical records state a serious neurological or endocrine disorder at screening that the investigator determines could interfere with the interpretation of the efficacy or safety measurements
  2. An abnormal at screening that the investigator determines could interfere with the interpretation of the efficacy or safety measurements
  3. Any medical condition which requires treatment with a medication with psychotropic effects.
  4. Significant risk of suicidal or homicidal behavior (i.e. 'severe' risk on the Columbia Suicide Scale, a 'hostility' score of 7 on the BPRS, or an answer of 'yes' on questions 4,5 or 6 on the CDSS).
  5. Cognitive limitations, or any other factor that would preclude potential participants providing
  6. to MRI (e.g. pacemaker).
  7. Meeting SCID-5 substance use disorder moderate or severe for any substance, other than nicotine within 3 months of screening visit. Meeting SCID5 substance use disorder mild for any substance other than cannabis, alcohol, or nicotine for less than 3 months prior to screening visit, or a positive urine baseline drug screen with a substance other than nicotine, alcohol, or cannabis
  8. Suspected DSM5 intellectual disability based upon clinical interview and psychosocial history, as well as screening with the Weschler Test for Adult Reading (IQ score \<71)
  9. Prior psychosurgery
  10. Pregnancy (self-report)
  11. Seizure disorder (self-report)

    -

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    risperidone

    risperidone treatment provided per protocol

    Drug: risperidone

  • Active comparator
    aripiprazole

    aripiprazole treatment per protocol

    Drug: aripiprazole

  • Active comparator
    clozapine

    clozapine treatment per protocol

    Drug: clozapine

Interventions

06

What researchers measure

Primary outcomes

  1. Total change in BPRS Symptoms

    To compare the 12-week response rate of CLZ versus FL-APs (both risperidone and aripiprazole) utilizing the BPRS

    Time frame: 12 weeks

Secondary outcomes

  1. Weight Gain

    To compare weight gain associated with 12 weeks of treatment with CLZ vs. FL-APs in 3B+ FEP patients.

    Time frame: 12 weeks

  2. Agranulocytosis

    To compare rates of agranulocytosis in 3B+ FEP patients treated for 12 weeks with CLZ vs. 3B+ FEP patients treated with FL-APs

    Time frame: 12 weeks

  3. Neutropenia

    To compare rates of neutropenia in 3B+ FEP patients treated for 12 weeks with CLZ vs. 3B+ FEP patients treated with FL-APs

    Time frame: 12 weeks

Other outcomes

  1. Functional MRI

    Evaluate changes in resting-state functional connectivity patterns related to CLZ response by comparing baseline to 12-week rs-fMRI scans

    Time frame: 12 weeks

  2. Functional Outcome

    To explore the days in hospital of CLZ-treated 3B+ FEP patients vs. 3B+ FEP patients treated with FL-

    Time frame: 12 weeks

  3. Functional Outcome

    To explore suicidal ideation of CLZ-treated 3B+ FEP patients vs. 3B+ FEP patients treated with FL-APs as measured by the CSSRS

    Time frame: 12 weeks

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All de-identified data will be placed in the NDA.

Time frame: The data will be transferred 12 months after the study starts and then every 6 months

Access criteria: Access to the NDA will be controlled by the NDA following their policies and procedures.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jul 2030, 70 months after the start.

Of 71 non-industry phase 4 interventional studies under Schizophrenia, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 70 months is above that.

Counting every sponsor, half of 88 studies reached it within 39 months; a quarter within 20 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2025
First posted
May 14, 2025
StartActual
Sep 4, 2024
Primary completionEst.
Jul 30, 2030
CompletionEst.
Jul 30, 2030
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06969755
Lead sponsor
Northwell Health
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Sep 4, 2024
Primary completion
Jul 30, 2030 (estimated)
Completion
Jul 30, 2030 (estimated)
Last update
Jul 31, 2026

Study contacts

Patricia Marcy
Contact
pmarcy@northwell.edu
904-302-0811
Cristina Gonzalez
Contact
cgomes@northwell.edu
347-804-3605

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aripiprazole · Risperidone · Clozapine

Start the discussion